| Quarter |
|---|
Growth YoY Revenue Growth YoY% |
OPM OPM% |
Interest Expense Interest ExpenseCr |
Depreciation DepreciationCr |
PBT PBTCr |
Growth YoY PAT Growth YoY% |
NPM NPM% |
| Quarter |
|---|
Growth YoY Revenue Growth YoY% |
OPM OPM% |
Interest Expense Interest ExpenseCr |
Depreciation DepreciationCr |
PBT PBTCr |
Growth YoY PAT Growth YoY% |
NPM NPM% |
| Financial Year | Mar 2026 |
|---|---|
Revenue RevenueCr | 147 |
Growth Revenue Growth% | |
| 117 | |
| 30 | |
OPM OPM% | 20.3 |
| 1 | |
Interest Expense Interest ExpenseCr | 0 |
Depreciation DepreciationCr | 4 |
PBT PBTCr | 27 |
| 7 | |
PAT PATCr | 21 |
Growth PAT Growth% | |
NPM NPM% | 14.0 |
| 9.3 |
| Financial Year | Mar 2026 |
|---|---|
Revenue RevenueCr | 147 |
Growth Revenue Growth% | |
| 117 | |
| 30 | |
OPM OPM% | 20.3 |
| 1 | |
Interest Expense Interest ExpenseCr | 0 |
Depreciation DepreciationCr | 4 |
PBT PBTCr | 27 |
| 7 | |
PAT PATCr | 21 |
Growth PAT Growth% | |
NPM NPM% | 14.0 |
| 9.3 |
| Financial Year |
|---|
Equity Capital Equity CapitalCr |
Reserves ReservesCr |
| Financial Year |
|---|
Equity Capital Equity CapitalCr |
Reserves ReservesCr |
| Financial Year | Mar 2026 |
|---|---|
| 4 | |
| -25 | |
| 45 | |
Net Cash Flow Net Cash FlowCr | 23 |
Free Cash Flow Free Cash FlowCr | |
CFO To PAT CFO To PAT% | 18.9 |
CFO To EBITDA CFO To EBITDA% | 13.0 |
| Financial Year | Mar 2026 |
|---|---|
| 4 | |
| -25 | |
| 45 | |
Net Cash Flow Net Cash FlowCr | 23 |
Free Cash Flow Free Cash FlowCr | |
CFO To PAT CFO To PAT% | 18.9 |
CFO To EBITDA CFO To EBITDA% | 13.0 |
| Financial Year | Mar 2026 | Current |
|---|---|---|
Market Cap Market CapitalizationCr | 468 | 641 |
Price To Earnings Price To Earnings | 22.8 | 31.2 |
Price To Sales Price To Sales | 3.2 | 4.4 |
Price To Book Price To Book | 4.6 | 6.4 |
EV To EBITDA EV To EBITDA | 20.4 | |
GPM GPM% | ||
OPM OPM% | 20.3 | 20.3 |
NPM NPM% | 14.0 | 14.0 |
ROCE ROCE% | ||
ROE ROE% | ||
ROA ROA% | ||
| Financial Year | Mar 2026 | Current |
|---|---|---|
Market Cap Market CapitalizationCr | 468 | 641 |
Price To Earnings Price To Earnings | 22.8 | 31.2 |
Price To Sales Price To Sales | 3.2 | 4.4 |
Price To Book Price To Book | 4.6 | 6.4 |
EV To EBITDA EV To EBITDA | 20.4 | |
GPM GPM% | ||
OPM OPM% | 20.3 | 20.3 |
NPM NPM% | 14.0 | 14.0 |
ROCE ROCE% | ||
ROE ROE% | ||
ROA ROA% | ||
Documents — Influx Healthtech Ltd
Concall Transcript Summaries — Influx Healthtech Ltd